Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Autoimmune hemolytic anemia
Autoimmune hemolytic anemia
Autoimmune hemolytic anemia
Synonyms: AHA, AIHA
Synonyms: AHA, AIHA
Synonyms: AHA, AIHA
Drug discovery
18
drugs
With orphan designations
Rare hematologic diseases
Autoimmune hemolytic anemia
Overview
Autoimmune Hemolytic Anemia (AIHA) is a rare immune disorder characterized by autoantibody-mediated destruction of red blood cells, leading to anemia. It is classified as warm AIHA (IgG antibodies active at 37°C) or cold AIHA (IgM antibodies reactive at lower temperatures). Symptoms range from fatigue, pallor, and jaundice to severe complications like thrombosis or organ failure. Diagnosis relies on direct antiglobulin (Coombs) testing, with subtyping guiding management [1][6][11].
Burden
One-year mortality: 17.9% (primary AIHA) to 28.4% (secondary AIHA) [2][15].
High healthcare utilization: 48% of severe cases require hospitalization; 55% need transfusions [4][2][15].
Long-term risks: Cardiovascular events, chronic immunosuppression-related infections, and reduced quality of life [2][15][16].
Therapies
First-line: Corticosteroids (prednisone) with response rates of 70–85% [8][12][14].
Refractory/relapsed cases: Rituximab (overall response: 75–90%), splenectomy (long-term remission in ~66%), or immunosuppressants (azathioprine, cyclosporine) [8][12][14].
Cold AIHA: Cold avoidance, rituximab, or complement inhibitors (e.g., sutimlimab under investigation) [6][14][16].
Categories: rare hematological diseases
Research Papers
1,504 drug discovery papers about Autoimmune hemolytic anemia, with 2 first-in-class and 19 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
1,504 drug discovery papers about Autoimmune hemolytic anemia, with 2 first-in-class and 19 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
small molecules
2026-09-30 | Case Report: Severe mixed autoimmune hemolytic anemia associated with acute cytomegalovirus infection in an immunocompetent adult.
Cytomegalovirus (CMV)-associated hemolytic anemia (HA) is rare in immunocompetent hosts and may present with heterogeneous serologic phenotypes, including direct antiglobulin test (DAT)-negative hemolysis, warm autoimmune hemolytic anemia (AIHA), cold antibody-mediated AIHA, and rarely mixed AIHA. Because mixed AIHA requires evidence of both warm autoantibodies and clinically significant cold autoantibody activity, this phenotype may be underrecognized without comprehensive immunohematologic testing. We report a case of CMV-associated HA that was diagnosed as mixed AIHA by comprehensive immunohematologic assessment and successfully managed with combination therapy. A 59-year-old immunocompetent man presented with a 7-day history of fever, sore throat, and fatigue. Initial evaluation revealed marked hepatocellular and cholestatic liver injury, positive CMV IgM with negative CMV IgG, and serum CMV DNA of 2.28 × 105 IU/mL. After exclusion of common viral and autoimmune causes, acute CMV hepatitis was clinically diagnosed. On hospital day 4, he developed dark brown urine, with hemoglobin falling to 40 g/L and laboratory evidence of acute hemolysis. Extended DAT revealed IgG, IgA, IgM, and C3d coating of erythrocytes, and cold agglutinin testing identified an IgM cold agglutinin with a titer of 1:128 and thermal amplitude extending to 37 °C, supporting severe CMV-associated mixed AIHA. After antiviral therapy, immunomodulatory and supportive treatment, hemolysis was controlled, and hemoglobin stabilized without further transfusion. CMV-associated HA may rarely present as severe mixed AIHA in immunocompetent adults. In severe or atypical cases, comprehensive immunohematologic evaluation beyond routine DAT, including extended DAT, cold agglutinin titration, and thermal amplitude testing, is essential for accurate subtyping. In severe cases, early integrated therapy targeting both CMV replication and immune-mediated hemolysis may be required.
2026-09-11 | DAT-negative autoimmune hemolytic anemia following acute hepatitis a in a pediatric patient with elevated IgA: a rare case report and literature review.
Acute hepatitis A (AHA) is typically self-limited, with complications occurring in only 0.1% of patients. Autoimmune hemolytic anemia (AIHA) following AHA is exceedingly rare; only four adult cases have been reported. We present the first documented pediatric case of DAT-negative AIHA following severe AHA. A 13-year-old Middle Eastern female presented with worsening jaundice, dark urine, and breathlessness 4 weeks after a confirmed AHA diagnosis. Laboratory evaluation revealed hemolysis: hemoglobin 8.1 g/dL, LDH 560 U/L, haptoglobin 0.14 g/L, reticulocyte count 7.28%, and indirect bilirubin 19.3 mg/dL. The direct antiglobulin test (DAT) was negative on three occasions. Extensive testing excluded Glucose-6-phosphate dehydrogenase deficiency, thalassemias, hereditary spherocytosis, malignancies, and other autoimmune diseases. Immunoglobulin studies showed elevated IgA (596.2 mg/dL) with normal IgG and IgM. Diagnosis of DAT-negative AIHA was established through the exclusion of hereditary causes and confirmed by a rapid response to prednisolone 1 mg/kg/day (hemoglobin rose from 8.1 to 10.4 g/dL within 1 week). This case highlights that 3-11% of AIHA cases are DAT-negative due to IgA or IgM antibodies or low-affinity IgG. DAT-negative AIHA should be suspected in unexplained post-viral hemolysis despite a negative DAT. Early empiric corticosteroids can be both diagnostic and therapeutic. Key clinical lessons: (1) DAT-negative AIHA accounts for 3-11% of cases and may be IgA-mediated; (2) Systematic exclusion of hereditary hemolytic anemias is essential in high-prevalence populations; (3) Rapid response to corticosteroids supports immune-mediated etiology and justifies continued treatment.
2026-08-24 | Bortezomib and autoimmune hemolytic anemia: a systematic review and meta-analysis
Conventional treatments for autoimmune hemolytic anemia (AIHA) are associated with drawbacks including high recurrence rates and limited therapeutic efficacy. As a proteasome inhibitor, bortezomib demonstrates potential value in relapsed/refractory AIHA, yet existing evidence mostly consists of small-sample case reports without quantitative integrated analyses. The results of this meta-analysis revealed that the pooled overall response rate (ORR) of bortezomib for AIHA was 81% (95%CI: 0.71–0.92), with extremely low inter-study heterogeneity (I²=0.0%, P=0.950). After excluding 2 conference abstracts, the pooled ORR of the remaining 4 full-text studies reached 82% (95%CI: 0.69–0.94), and leave-one-out sensitivity analysis identified no single study exerting a significant impact on the overall conclusions. Current evidence indicates that bortezomib can serve as a second-line salvage therapy for relapsed/refractory patients. However, the included studies were predominantly single-arm retrospective small-sample trials, lacking long-term safety data, failing to differentiate therapeutic effects between warm-type AIHA and cold agglutinin disease subgroups, and containing no controlled trials for direct comparisons with conventional regimens. In conclusion, bortezomib delivers stable efficacy and acceptable tolerability in relapsed/refractory AIHA. Large-sample, multicenter, prospective controlled studies are still required to clarify the optimal administration regimen, eligible patient populations and long-term safety profiles.
2026-08-10 | Autoimmune hemolytic anemia in the era of immunotherapy: from pathogenesis to therapeutic strategies
Abstract Autoimmune hemolytic anemia (AIHA) is a rare hematologic disorder characterized by the accelerated destruction of red blood cells mediated by autoantibodies and is classified into warm antibody type and cold antibody type. Corticosteroids remain the first-line treatment, whereas rituximab has replaced splenectomy as the standard second-line therapy. However, a considerable proportion of patients still experience relapse or refractory disease. In recent years, with an improved understanding of its pathogenesis, significant advances have been achieved in targeted therapies for AIHA, including complement inhibitors, spleen tyrosine kinase inhibitors, Bruton tyrosine kinase inhibitors, phosphoinositide 3-kinase delta inhibitors, other novel agents, and chimeric antigen receptor T-cell therapy. Future AIHA management will focus on individualized treatment guided by precise stratification, combination strategies, and biomarkers, ultimately achieving a transition from empirical immunosuppression to mechanism-targeted precision medicine.
2026-08-04 | Early-Onset Direct Antiglobulin Test-Negative Autoimmune Hemolytic Anemia Induced by Pembrolizumab in Perioperative Triple-Negative Breast Cancer: A Case Report.
Hematological immune-related adverse events associated with immune checkpoint inhibitors (ICIs) are rare, and autoimmune hemolytic anemia (AIHA) is particularly uncommon. A 71-year-old woman with stage IIA triple-negative breast cancer received perioperative pembrolizumab with carboplatin and paclitaxel. During the first treatment cycle, she developed acute severe anemia with laboratory findings consistent with hemolysis. Despite a negative direct antiglobulin test (DAT), major alternative causes of hemolysis were considered unlikely, leading to a clinical diagnosis of suspected ICI-associated AIHA. Oral prednisolone (1 mg/kg) promptly resolved hemolysis without recurrence. Pembrolizumab was discontinued; however, imaging demonstrated a clinical complete response, and subsequent surgery confirmed a pathological complete response (pCR). This case demonstrates that AIHA during ICI therapy may occur despite a negative DAT and underscores the importance of prompt recognition and corticosteroid therapy. Favorable oncologic outcomes, including pCR, may still be achieved despite early discontinuation of ICI therapy.
cell therapies
2026-09-11 | Therapeutic plasma exchange across multiple organ systems in an Egyptian tertiary center: A seven-year real-world cohort study.
Real-world evidence on therapeutic plasma exchange (TPE) from low- and middle-income countries remains limited. Egyptian data across multiple organ systems are scarce. This study aimed to evaluate the indications, safety, efficacy, and predictors of outcomes in patients undergoing TPE at a tertiary center in Egypt over 7 years. This retrospective cohort study included 221 consecutive patients who underwent TPE (2016-2022) at Zagazig University Hospitals, Egypt. Patients were stratified into renal, neurologic, hematologic, and metabolic groups. Primary outcomes were clinical response and all-cause mortality. Multivariate logistic regression, Cox proportional hazards models, and Kaplan-Meier survival analysis were performed. Among 221 patients (57.9% male; mean age 36.0 years), the most frequent indications were Guillain-Barré syndrome, thrombotic thrombocytopenic purpura, and myasthenia gravis crisis. ASFA category I indications constituted 77.8% of procedures, with response rates decreasing significantly across categories (p = 0.03). Overall response rate was 77.9% (complete remission in 93.0% of responders), with mortality 14.5%. Response rates exceeded 85% in autoimmune hemolytic anemia, hyperviscosity syndrome, and TTP. Neurologic indications achieved 81.6% response; renal indications showed lower response (73.2%) and highest mortality (21.3%). Adverse events occurred in 37.2% of patients, all mild-to-moderate with no session terminations. Independent mortality predictors included mechanical ventilation, creatinine >2.5 mg/dL, renal indication, hemoglobin <8 g/dL, while ASFA category I was protective (all aORs 2.67-5.22). In exploratory analyses, PLASMIC score ≥6 and time to TPE ≤ 2 days were associated with complete remission in TTP, while Hughes score ≥4 and time to TPE > 7 days were associated with poor functional outcome in GBS. These findings require external validation before clinical application. Diffuse alveolar hemorrhage (n = 9) demonstrated 100% mortality despite intervention, whereas SLE patients (n = 23) had 52.2% mortality, with 47.8% achieving complete remission or clinical improvement. A three-tier risk model stratified patients into high, intermediate, and low mortality risk groups. Independent predictors of clinical response included neurologic, hematologic, and metabolic indications compared to renal, ASFA category I, and ≥5 TPE sessions, while hemoglobin <8 g/dL and creatinine >2.5 mg/dL predicted poorer response. This single-center Egyptian TPE cohort demonstrates high efficacy and safety when aligned with ASFA guidelines. Neurologic and hematologic indications achieve optimal outcomes; renal indications and critical illness markers predict poorer prognosis. The PLASMIC score, treatment urgency in TTP and GBS, and the proposed three-tier model represent exploratory findings that, if prospectively validated, could become actionable prognostic tools. These findings suggest that evidence-based TPE expansion in resource-limited settings may be feasible, though multicenter validation is required.
2026-07-17 | Long-Term Survival, Illness Severity, and Time-to-Treatment Analysis in Dogs with Immune-Mediated Hemolytic Anemia Following Intravenous Allogeneic Mesenchymal Stem Cell Therapy: A Multicohort Follow-Up Study.
Steroid-refractory immune-mediated hemolytic anemia (IMHA) in dogs carries high early mortality, and the 15%-30% of cases that fail corticosteroid-based therapy represent a population with few effective options and a narrowing treatment window. In a prior retrospective study, intravenous allogeneic mesenchymal stem cell (MSC) therapy achieved a 76.7% hematological success rate in 43 dogs with steroid-refractory IMHA. The present multicohort follow-up study extends that work by characterizing illness severity, time-to-treatment, and long-term survival across 137 eligible patients from the same database. In Kaplan-Meier analysis of all 137 eligible patients, comprising both the nonsurvivor cohort (n = 57) and the lifespan registry (n = 80), median survival was 1,695 days (4.6 years) in the primary cohort and was not reached in the protocol-assessable cohort (n = 120). Estimated 1-year survival was 56.9% (95% CI: 48.2%-64.7%) and 65.0% (95% CI: 55.7%-72.8%), respectively, and the survival probability stabilized at approximately 52% through 8.1 years of follow-up. Among the 57 nonsurvivors, 51 had sufficient diagnostic data to calculate a Canine Hemolytic Anemia Objective Score (CHAOS) score; two-thirds (66.7%) met the high-risk threshold (CHAOS ≥ 3) at diagnosis. This exceeds the approximately 50% estimated from a published multicenter reference population, indicating that the Safari nonsurvivor cohort was enriched for severely ill dogs at presentation. Median post-treatment survival in nonsurvivors was 8 days (IQR: 3-38), and dogs receiving only one MSC dose had markedly shorter survival than those receiving two or more (median 4 vs. 19 days, P < 0.01), consistent with fulminant disease limiting completion of therapy rather than treatment failure. Diagnosis-to-treatment delay was shorter in survivors than in nonsurvivors (median 13 vs. 25 days), an exploratory finding warranting prospective evaluation. Taken together, these findings suggest that nonsurvival reflects the severity of the underlying disease and that dogs who respond to MSC therapy have potential for durable multiyear remission.
2026-07-06 | Immune cell-derived membrane nanovesicles: A promethean fire for autoimmune disease therapy through immune cell mimicry.
Autoimmune diseases (AIDs) constitute a heterogeneous group of disorders characterized by immune dysregulation, loss of self-tolerance, and chronic inflammation, which leads to tissue damage and organ dysfunction. Current therapies for AIDs are often limited by their lack of specificity, systemic side effects, and insufficient restoration of immune tolerance. Recent advances in nanotechnology and bioengineering have introduced immune and associated cell-derived membrane vesicles (IACMVs) as a promising therapeutic platform. Derived from macrophages, dendritic cells, neutrophils, platelets, or red blood cells, IACMVs inherit key surface proteins and receptors from their parent cells, conferring endogenous biocompatibility, inflammation-specific targeting, and intrinsic immunomodulatory capabilities. These vesicles can be engineered to carry therapeutic cargoes (e.g., peptide inhibitors, nucleic acids) or modified with surface ligands to enhance disease-site specificity, making them versatile tools for specific immunomodulation. This review provides a comprehensive overview of IACMVs, focusing on their preparation techniques, functional mechanisms, and therapeutic applications in prototypical AIDs such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), autoimmune hemolytic anemia (AIHA), type 1 diabetes (T1D), multiple sclerosis (MS), and autoimmune myocarditis (AM). We highlight translational challenges, including production scalability, membrane integrity, immunogenicity, and cargo-loading efficiency, that must be addressed to advance clinical translation. Finally, we discuss future directions for optimizing IACMVs as next-generation, safe, and targeted immunotherapeutic platforms for AIDs.
2026-06-03 | Stealth red blood cells with broad-spectrum antigenic shielding for transfusion therapy in antibody-mediated hemolytic anemia.
Red blood cell (RBC) transfusion is a cornerstone of life-sustaining therapy, yet it is profoundly challenged in autoimmune hemolytic anemia (AIHA). In this disorder, a diverse array of autoantibodies targets both the autologous and transfused RBCs, leading to their rapid clearance. This limitation is especially severe during hemolytic crises, rendering conventional transfusion ineffective and eliminating a critical therapeutic option. To overcome this, we developed a biocompatible strategy by utilizing a microbial transglutaminase that first anchors to the RBC membrane and then crosslinks a polysialic acid (PSA) network onto the cell surface. This created an immunologically inert shield that broadly masks surface antigens from pathogenic antibodies. Crucially, this "stealth" modification preserved the RBCs' native biological functions, including essential gas exchange, while conferring robust resistance to antibody-mediated hemolysis. In vitro, the engineered RBCs were protected from antibody binding and macrophage phagocytosis. This protection translated to a significantly prolonged circulation time in AIHA murine models and demonstrated excellent biocompatibility in an allogeneic transfusion setting. Our findings underscore the significant potential of this platform to enable effective, life-saving transfusion therapies for AIHA and other antibody-mediated disorders.
2026-05-02 | A case of autoimmune hemolytic anemia with acquired functional mutation of the TLR7.
This article presents a case of recurrent autoimmune hemolytic anemia in a child with a gain-of-function (GOF) mutation of the TLR7. This patient's condition contrasts with the six previously documented cases of GOF mutations in the TLR7, thereby expanding the phenotypic spectrum of such mutations and enhancing clinical comprehension of childhood systemic lupus erythematosus (cSLE). The article discusses the mechanisms by which TLR7 GOF mutations can result in autoimmune hemolytic anemia, explores the influence of cytomegalovirus (CMV) infection on the disease's development and progression, and emphasizes the therapeutic potential of hematopoietic stem cell transplantation for cases of TLR7 GOF mutations.
proteins
2026-05-18 | Case Report: Different faces of LRBA deficiency in five Moroccan families.
LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency belonging to the spectrum of common variable immunodeficiency disorders, frequently associated with immune dysregulation, autoimmunity, and lymphoproliferation. Its clinical presentation is highly heterogeneous, ranging from isolated autoimmune cytopenias to severe multisystem involvement. Here, we report five cases of LRBA deficiency from five Moroccan families, highlighting the broad clinical variability of this condition. The first patient presented with chronic immune thrombocytopenic purpura (ITP) as the initial and predominant manifestation, associated with hypogammaglobulinemia. The second patient developed ITP complicated by a hemorrhagic syndrome and significant lymphoproliferation, including splenomegaly and hepatomegaly. The third patient initially presented with autoimmune hemolytic anemia (AIHA), followed by splenomegaly. The fourth patient exhibited a complex clinical course, beginning with bicytopenia and progressing to enteropathy, arthritis, pneumopathy, and type 1 diabetes mellitus, associated with splenomegaly, hepatomegaly, and lymphadenopathy. Finally, the fifth patient initially presented with ITP and subsequently developed bilateral panuveitis, arthritis, and recurrent respiratory infections. Targeted next-generation sequencing identified homozygous pathogenic variants in the LRBA gene in all five patients, consistent with a loss-of-function mechanism. These included the nonsense variants c.3811C>T (p.Arg1271*) and c.5692G>T (p.Glu1898*), a large deletion encompassing exons 30 to 34, the frameshift variant c.5060_5067delACATACCA (p.Asn1687Serfs*21), and an extended deletion involving part of exon 4 (c.476_549 + 580del). All patients required immunosuppressive therapy and/or immunoglobulin replacement. LRBA deficiency should be considered in children presenting with autoimmune cytopenias, lymphoproliferation, and multisystem autoimmunity. The marked heterogeneity of clinical manifestations underscores the importance of early molecular diagnosis to guide therapeutic decision-making. In our experience, prompt recognition and the initiation of targeted therapies, such as abatacept or early hematopoietic stem cell transplantation, may improve patient outcomes.
2025-11-03 | Mixed autoimmune hemolytic anemia as a rare initial presentation of systemic lupus erythematosus
Abstract Introduction: Autoimmune hemolytic anemia (AIHA) is a rare disorder in which autoantibodies produced by the immune system attach to red blood cells, leading to their premature destruction. It is primarily divided into warm IgG antibodies (65% prevalence), cold C3 antibodies (15-20% prevalence), and mixed IgG and C3 antibodies (10% prevalence) based on antibody agglutination temperature. Mixed autoimmune hemolytic anemia (MAIHA) is an exceedingly rare disorder that usually presents as severe anemia with a median hemoglobin of 6. We report a rare case of a patient who presented with MAIHA as an initial presentation of SLE. Case Description:A 22-year-old Hispanic female, with no past medical history, presented to the emergency department with complaints of RUQ abdominal pain, fatigue, and dark discoloration of urine for 2 weeks. Initial labs showed a hemoglobin of 5.3 g/dL, an RBC count of 1.28 million/mcL, MCV of 126 fL, an elevated total bilirubin of 2.7 mg/dL (with an indirect bilirubin of 2.1 mg/dL), a high LDH of 278 U/L, and a significantly low haptoglobin of less than 30 mg/dL. The Direct Coombs Test (DAT) was positive with both polyspecific and C3 reagents, and the Antibody Screen was positive on both the Immediate Spin and Prewarm Indirect Coombs tests. Furthermore, a positive antibody screen was noted, and both warm and cold autoantibodies were identified. Iron studies, folate, and B-12 levels were within normal limits. The patient was started on immunosuppressive therapy for mixed autoimmune hemolytic anemia with prednisone 1 mg per kilogram divided into twice daily dosing and IVIG 1g/kg for two doses. She did not receive any blood transfusion because of no overt signs of bleeding and lack of availability of cross-matched blood. Her hemoglobin improved to 5.8 after the first dose of steroids and IVIG. On further testing, infectious workup was negative for influenza virus, RSV, SARS-CoV-2, HIV, hepatitis panel, EBV, and CMV. C4 levels were low at 9, and C3 levels were normal. Her ANA screen was positive, and the double-stranded DNA antibody level was 18 UL/ml. The patient met SLICC criteria for SLE, manifested with positive ANA by IFA 1:1280, positive dsDNA, low complement level, and hemolytic anemia. The patient continued to improve on prednisone. She was discharged on the eighth day of her hospitalization on oral prednisone at 45 mg twice daily. Her hemoglobin on the day of discharge was 7.6 g/dL, hematocrit 21.7%, and the RDW was 24.5% Discussion: MAIHA is associated with autoimmune diseases, lymphoproliferative disorders, and infections. SLE is the most common autoimmune disorder associated with mixed AIHA. Autoimmune hemolysis occurs in about 10% of patients with SLE; however, MAIHA is rarely the presenting feature. The primary treatment of MAIHA is corticosteroid therapy and avoiding exposure to cold. Our patient achieved remission with steroids and IVIG. We preferred IVIG as it is faster acting than rituximab and has fewer side effects. IVIG inhibits extravascular hemolysis by saturating the reticuloendothelial system. Most patients require more than one therapeutic intervention for AIHA.Conclusion: This case highlights that although rare, SLE can present with MAIHA. SLE should be considered as one of the causes of MAIHA, and clinicians should have a high clinical suspicion for it.
2025-06-12 | Evans Syndrome and COVID-19 Infection or Vaccination: A Systematic Review of Case Reports.
Evans syndrome (ES) is an autoimmune disorder of unknown etiology characterized by autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). In this systematic review, we analyzed the reported cases of ES secondary to coronavirus disease 2019 (COVID-19) infection or COVID-19 vaccination. We examined their clinical presentation, temporality between events, diagnostics tests, and treatment regimens. Our search in four databases from December 2019 to September 2023 yielded 16 case reports that met eligibility criteria for inclusion. COVID-19 and ES symptoms were defined to assess the timeline between infection/vaccination and ES onset. Finally, treatment efficacy was categorized as complete, partial, or no response based on standard hematological criteria. Eleven cases of ES were associated with COVID-19 infection, and five cases of ES were associated with COVID-19 vaccination. All 16 cases presented with anemia, thrombocytopenia, and a positive Coombs test. Four of the five patients from the vaccination subset were found to have an additional autoimmune disease as a comorbidity on presentation. For cases of ES secondary to COVID-19 infection, six patients had concomitant symptoms of COVID-19 and ES on presentation, and four patients had ES symptoms occurring from 5 days to 3 weeks following COVID-19 infection. The remaining case presented a patient with a 3-week history of ES symptoms before a positive COVID-19 test and further ES workup on admission. For the five cases of ES post-COVID-19 vaccination, all five patients presented with ES with a mean presentation time of 9 days following vaccination. Regarding treatment, intravenous immunoglobulin (IVIG) emerged as the primary regimen, administered in 13 out of the 16 cases. Among the infection-related cases, the most frequent treatment outcome was a partial response in both AIHA and ITP, observed in five of the 11 patients. In the vaccination-related cases, a partial response for AIHA and a complete response for ITP were noted in three of the five patients. Overall, while the evidence points to a temporal association especially between COVID-19 vaccination and the onset of ES, larger studies are necessary to strengthen these findings. In terms of management, early initiation of corticosteroids and IVIG appears effective as first-line therapies; however, standardized treatment protocols are needed to help reduce complications associated with COVID-19-related ES.
2025-04-18 | Epstein-Barr virus-associated autoimmune hemolytic anemia: a clinical report and review of literature.
Epstein-Barr virus (EBV) infection is a common disease both in children and adults, but can lead to several complications; involvement of the blood system is often described, particularly neutropenia and thrombocytopenia, but autoimmune hemolytic anemia is rarely seen. A 12-year-old female was admitted to the "G. Di Cristina" Children's Hospital of Palermo for jaundice and dark urine. Laboratory investigations revealed anemia, increased levels of total and undirect bilirubin, and elevated transaminases, serum lactate dehydrogenase, and reticulocyte count; a peripheral blood smear showed anisocytosis, and the direct antiglobulin test (DAT) for cold agglutinins was positive. The laboratory evaluation of infectious disease showed the presence of EBV VCA IgM and IgG. A diagnosis of acute autoimmune hemolytic anemia EBV related was made: the patient was initially treated with intravenous methylprednisolone and then with intravenous immunoglobulin, which led to a progressive clinical improvement until complete remission. Autoimmune hemolytic anemia is rarely associated with EBV infection; a review of the English literature revealed only 16 cases. Patients with autoimmune hemolytic anemia should always be evaluated for EBV serology, even in the absence of the typical clinical and hematological features of infectious mononucleosis. For these patients, good prognosis is generally expected.
2024-10-23 | Potent efficacy of an IgG-specific endoglycosidase against IgG-mediated pathologies.
Endo-β-N-acetylglucosaminidases (ENGases) that specifically hydrolyze the Asn297-linked glycan on immunoglobulin G (IgG) antibodies, the major molecular determinant of fragment crystallizable (Fc) γ receptor (FcγR) binding, are exceedingly rare. All previously characterized IgG-specific ENGases are multi-domain proteins secreted as an immune evasion strategy by Streptococcus pyogenes strains. Here, using in silico analysis and mass spectrometry techniques, we identified a family of single-domain ENGases secreted by pathogenic corynebacterial species that exhibit strict specificity for IgG antibodies. By X-ray crystallographic and surface plasmon resonance analyses, we found that the most catalytically efficient IgG-specific ENGase family member recognizes both protein and glycan components of IgG. Employing in vivo models, we demonstrated the remarkable efficacy of this IgG-specific ENGase in mitigating numerous pathologies that rely on FcγR-mediated effector functions, including T and B lymphocyte depletion, autoimmune hemolytic anemia, and antibody-dependent enhancement of dengue disease, revealing its potential for treating and/or preventing a wide range of IgG-mediated diseases in humans.
antibodies
2026-09-27 | Autoimmune Hemolytic Anemia Complicated by Portal Vein Thrombosis in a Pediatric Liver Transplant Recipient: A Case Report.
Post-transplant autoimmune hemolytic anemia (AIHA) occurs in approximately 1% to 3% of pediatric liver transplant recipients. Its co-occurrence with portal vein thrombosis (PVT) is exceedingly rare and potentially life-threatening. We report a 10-month-old female who underwent living-donor liver transplantation for biliary atresia and presented with AIHA 5 months later. Laboratory evaluation revealed severe hemolytic anemia (hemoglobin 7.5 g/dL), markedly elevated lactate dehydrogenase (1751 IU/L), hyperbilirubinemia (total bilirubin 4.92 mg/dL), thrombocytopenia (75 × 103/μL), prolonged PT/INR, critically reduced Protein S activity (48.1%), and elevated D-dimer (3.78 mg/L; 7.6 × upper normal). A strongly positive Direct Antiglobulin Test confirmed AIHA. Abdominal computed tomography demonstrated hepatomegaly with portal vein thrombosis, confirmed by color-flow Doppler ultrasonography with turbulent, reduced flow. Tacrolimus dose was reduced and simultaneous high-dose methylprednisolone (4 mg/kg/d intravenously), rituximab, and therapeutic heparin were initiated. Complete portal vein recanalization was confirmed by Doppler on Day 5, with full immunologic remission (Direct Antiglobulin Test-negative) thereafter. This case demonstrates that post-transplant AIHA can precipitate PVT through a hemolysis-driven hypercoagulable cascade involving Protein S consumption, thrombocytopenia, and pro-coagulant erythrocyte microparticle release. Systematic coagulation profiling and Doppler ultrasonography at AIHA onset are mandatory in pediatric liver transplant recipients to prevent potentially fatal vascular complications.
2026-09-26 | Pediatric DOCK8 Deficiency Beyond Infections and Atopy: An Immunoactinopathy with Immune Dysregulation and Multisystem Involvement.
Background/Objectives: Dedicator of cytokinesis 8 (DOCK8) deficiency is an autosomal recessive combined immunodeficiency and an actin cytoskeleton-related inborn error of immunity characterized by severe atopy, recurrent infections, and broad immune dysregulation. We aimed to describe the clinical, immunological, genetic, treatment-related, and outcome features of children with genetically confirmed DOCK8 deficiency, emphasizing immune dysregulation and systemic involvement. Methods: We retrospectively reviewed 17 pediatric patients from 14 unrelated kindreds with genetically confirmed DOCK8 deficiency followed at a tertiary pediatric immunology center between 2005 and 2026. Demographic data, infectious and allergic manifestations, autoimmune and hematological findings, organ involvement, malignancy, laboratory parameters, genetic findings, hematopoietic stem cell transplantation (HSCT) status, and survival outcomes were analyzed descriptively. Results: Twelve patients were male (70.6%), and parental consanguinity was present in 13 patients (76.5%). The median age at symptom onset was 5 months (IQR, 3-10), whereas the median age at diagnosis was 44 months (IQR, 23-56). A history of eczema was documented in all patients. Recurrent skin infections occurred in 16 patients (94.1%), recurrent pneumonia in 13 (76.5%), mucocutaneous candidiasis in 10 (58.8%), and cytomegalovirus infection in four (23.5%). Confirmed autoimmune manifestations were documented in two patients, including autoimmune hepatitis and autoimmune hemolytic anemia. Malignancy occurred in two patients: gastrointestinal stromal tumor and cutaneous squamous cell carcinoma. Additional uncommon systemic manifestations included sclerosing cholangitis, giant aortic aneurysm, and chronic pancreatitis. HSCT was performed in 12 patients (70.6%); complete clinical recovery was achieved in 11, whereas one patient died after transplantation. Four of five non-transplanted patients died during follow-up. Conclusions: Pediatric DOCK8 deficiency showed an early-onset, severe, multisystem phenotype. Beyond infections and atopy, immune dysregulation-related and systemic manifestations were clinically important. Favorable HSCT outcomes were consistent with previous evidence supporting early molecular diagnosis and timely transplant evaluation.
2026-09-25 | Mixed Autoimmune Hemolytic Anemia as the Initial Manifestation of Systemic Lupus Erythematosus: A Case Report
Mixed autoimmune hemolytic anemia (mAIHA) is a rare subtype of autoimmune hemolytic anemia (AIHA) characterized by the coexistence of warm (immunoglobulin G (IgG)) and cold (immunoglobulin M (IgM)) autoantibodies.It may occur as a primary disorder or secondary to underlying conditions, including systemic lupus erythematosus (SLE).We report the case of a 16-year-old female who presented with severe hemolytic anemia as the initial manifestation of SLE.On admission, her hemoglobin was 34 g/L with marked reticulocytosis and a positive direct antiglobulin test (DAT) demonstrating both IgG and IgM antibodies, confirming mAIHA.Immunological investigations revealed positive antinuclear antibody (ANA), antidouble-stranded DNA (anti-dsDNA) antibody, and anti-Smith antibody, supporting a diagnosis of SLE.At the time of the first presentation, she had no other clinical features suggestive of SLE.She was treated with blood transfusions and corticosteroids, resulting in significant improvement, and was discharged on a tapering prednisolone regimen.Shortly after, she was readmitted with a malar rash, arthralgia, joint swelling, nephrotic-range proteinuria, and worsening renal function.She was subsequently diagnosed with SLE complicated by lupus nephritis and recurrent AIHA.Following the rheumatology and nephrology review, she received intravenous methylprednisolone and was transferred to a tertiary care center for renal biopsy and further management.Renal biopsy demonstrated focal segmental glomerulosclerosis (FSGS).Further treatment with prednisolone, mycophenolate mofetil, intravenous belimumab, and hydroxychloroquine resulted in an excellent clinical response, with follow-up confirming remission.This case highlights mAIHA as a rare initial presentation of SLE and underscores the importance of early recognition, close monitoring, and multidisciplinary management, as patients presenting with AIHA may be at increased risk of developing lupus nephritis and other severe SLE-related complications.
2026-09-24 | Sustained clinical stability with telitacicept-containing maintenance therapy following glucocorticoid and IVIG induction for lupus enteritis with autoimmune hemolytic anemia: a case report.
Lupus mesenteric vasculitis (LMV) is a rare but potentially life-threatening complication of systemic lupus erythematosus, with reported mortality rates of up to 13.4% despite aggressive immunosuppression. Standard management relies on high-dose glucocorticoids (GCs) combined with cyclophosphamide (CYC) or mycophenolate mofetil (MMF); however, prolonged glucocorticoid dependence and disease recurrence remain significant clinical challenges. Telitacicept, a recombinant transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI)-Fc fusion protein that simultaneously neutralizes B-lymphocyte stimulator and a proliferation-inducing ligand, has demonstrated efficacy in active SLE, yet evidence for its use in LMV is limited to a single case report. We describe a 27-year-old female with severe, glucocorticoid-dependent LMV complicated by autoimmune hemolytic anemia (AIHA), who received pulse methylprednisolone (MP) and intravenous immunoglobulin (IVIG) for acute induction, followed by telitacicept 160 mg weekly as part of a combination maintenance regimen. After conventional induction, telitacicept was associated with successful prednisone tapering from 60 mg/day to 10 mg/day over approximately 6 months without disease flare, accompanied by sustained normalization of hemoglobin and complement levels, and radiological improvement. This case represents the second report of telitacicept for LMV and the first to document sustained resolution of AIHA maintained during telitacicept-containing therapy. The induction with pulse MP followed by telitacicept maintenance and accelerated steroid taper" strategy may offer a promising therapeutic option for refractory LMV warranting further prospective investigation.
2026-09-14 | IgA driven autoimmune hemolytic anemia: a monocentric Italian report and literature review.
Atypical autoimmune hemolytic anemias (AIHA) include DAT-negative forms and those driven by IgA autoantibodies. IgA-mediated AIHA is rare, with limited evidence on clinical severity and management beyond first-line steroids. We revised our series of IgA-mediated AIHA and reviewed the literature. We retrospectively evaluated patients with IgA-positive AIHA followed at a tertiary hematologic center in Milan since May 1978. Published reports from 2010 to January 28, 2025 were also reviewed. Thirteen patients with IgA-mediated AIHA were identified among 409 AIHA cases. Median age was 60 years, and 69.2% were female. Fatigue was the most common symptom; mean hemoglobin was 7.9 g/dL. Dual IgA/IgG positivity occurred in 69.2%, while triple IgA/IgG/IgM positivity occurred in 7.7%. All but one patient received corticosteroids, 33% rituximab, 16.6% IVIg, and 23.1% transfusions. One patient received bortezomib followed by mycophenolate mofetil and plasma exchange. During a median follow-up of 36 months, 63.6% relapsed. Infections and thrombotic events occurred in 16.7% each, with no deaths. The literature review included 35 patients from 19 studies. Most were female (62%), aged 3 months to 77 years. Tachycardia and dyspnea were the most common symptoms; mean hemoglobin was 5.6 g/dL. DAT showed dual IgA/IgG or IgA/IgM positivity in 54.3%. Corticosteroids were administered to all reported patients, IVIg and rituximab to 14% and 23%, respectively. Splenectomy was performed in 6%, and 93% received transfusions. Infections occurred in 14%, thrombotic events in 7.1%, and one patient was refractory and died. IgA-mediated AIHA is a rare, heterogeneous subtype characterized by frequent dual antibody positivity, suboptimal corticosteroid response, and substantial risks of relapse and complications, requiring careful monitoring and individualized management. These findings highlight the need for improved recognition of IgA-mediated disease and prospective studies to define optimal second-line therapies and outcomes in affected patients.
other
2025-08-22 | From Yellow Cumulus to Pregnancy in Autoimmune Hemolytic Anemia Following Bilirubin Reduction: A Case Report.
Autoimmune hemolytic anemia (AIHA) is a systemic condition associated with inflammation and oxidative stress, both of which can negatively affect reproductive outcomes. Bilirubin, a byproduct of hemolysis, has been implicated in oocyte maturation and embryogenesis. We present the case of a 31-year-old patient with primary infertility who was known with AIHA. She had a total bilirubin level of 60 µmol/L prior to the first stimulation cycle, which was associated with yellowish pigmentation of the cumulus cells, poor oocyte quality, and no blastocyst formation. The decline in the total bilirubin level to 48 µmol/L after prednisone therapy of 60 mg daily for three months led to improved cumulus cell appearance and enhanced oocyte and embryo quality in the second stimulation cycle. A successful pregnancy was achieved following frozen blastocyst transfer in a natural cycle. This case underscores the importance of individualized assessment and the careful interpretation of elevated bilirubin levels in the context of assisted reproductive technology, as systemic conditions may potentially impact reproductive success.
2025-05-20 | Mixed Autoimmune Hemolytic Anemia: A Systematic Review of Epidemiology, Clinical Characteristics, Therapies, and Outcomes.
Mixed autoimmune hemolytic anemia (AIHA) is a rare and clinically complex hematologic disorder defined by the simultaneous presence of both warm and cold autoantibodies, resulting in severe and often treatment-resistant hemolysis. Due to variability in diagnostic criteria and limited data, a comprehensive understanding of its epidemiology, clinical characteristics, and management remains incomplete. To address these gaps, we performed a systematic literature review employing stringent diagnostic criteria to evaluate epidemiologic patterns, clinical features, and therapeutic outcomes. Our analysis included 81 patients identified across 35 studies, revealing a median age of 45 years and a notable female predominance (2.25:1). Autoimmune diseases constituted the most frequent underlying etiology, followed by hematologic malignancies and infections. Patients exhibited significant anemia, with median nadir hemoglobin levels reaching 5.6 g/dL. Corticosteroids represented the most common therapeutic intervention; however, only 43% of patients achieved remission, while 37% experienced chronic hemolysis, and mortality reached 11%. Many patients required multiple lines of therapy, including rituximab and cytotoxic agents, highlighting the disease's refractory nature and management complexity. The substantial variability in diagnostic and therapeutic approaches emphasizes an urgent need for standardized diagnostic criteria, earlier integration of combination therapies, and exploration of innovative treatment modalities. Future prospective, multicenter studies are essential to refine disease recognition, optimize therapeutic strategies, and ultimately improve patient outcomes in mixed AIHA.
2024-08-19 | Association of paediatric autoimmune cytopenia and inflammatory bowel disease suggests a common genetic origin.
The association of autoimmune cytopenia (AIC) and inflammatory bowel disease (IBD) has been reported in small series, but the incidence of and risk factors for IBD in children with AIC are not known. One thousand six hundred nine children with chronic immune thrombocytopenic purpura, autoimmune haemolytic anaemia or Evans syndrome from the prospective OBS'CEREVANCE cohort are included in this study. Overall, 15 children were diagnosed with IBD, including 14 who developed IBD after AIC diagnosis (median delay: 21 months). The only risk factor for IBD development is age at AIC over 10 years. Out of 10 children genetically tested, germline variants associated with autoimmune disorders were identified in three (CTLA4: two, DOCK11: one). In children and adolescents monitored for AIC or past history of AIC, especially children over 10 years, gastro-intestinal (GI) symptoms (recurrent abdominal pains, GI bleeding, chronic diarrhoea, weight loss) should suggest IBD and deserve specific work-up and genetic studies. Identification of a causal germline variant will allow targeted therapy.
2022-04-26 | Pathogenesis of Autoimmune Cytopenias in Inborn Errors of Immunity Revealing Novel Therapeutic Targets.
Autoimmune diseases are usually associated with environmental triggers and genetic predisposition. However, a few number of autoimmune diseases has a monogenic cause, mostly in children. These diseases may be the expression, isolated or associated with other symptoms, of an underlying inborn error of immunity (IEI). Autoimmune cytopenias (AICs), including immune thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA), autoimmune neutropenia (AN), and Evans' syndrome (ES) are common presentations of immunological diseases in the pediatric age, with at least 65% of cases of ES genetically determined. Autoimmune cytopenias in IEI have often a more severe, chronic, and relapsing course. Treatment refractoriness also characterizes autoimmune cytopenia with a monogenic cause, such as IEI. The mechanisms underlying autoimmune cytopenias in IEI include cellular or humoral autoimmunity, immune dysregulation in cases of hemophagocytosis or lymphoproliferation with or without splenic sequestration, bone marrow failure, myelodysplasia, or secondary myelosuppression. Genetic characterization of autoimmune cytopenias is of fundamental importance as an early diagnosis improves the outcome and allows the setting up of a targeted therapy, such as CTLA-4 IgG fusion protein (Abatacept), small molecule inhibitors (JAK-inhibitors), or gene therapy. Currently, gene therapy represents one of the most attractive targeted therapeutic approaches to treat selected inborn errors of immunity. Even in the absence of specific targeted therapies, however, whole exome genetic testing (WES) for children with chronic multilineage cytopenias should be considered as an early diagnostic tool for disease diagnosis and genetic counseling.
2020-01-09 | Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes.
Evans syndrome (ES) is a rare severe autoimmune disorder characterized by the combination of autoimmune hemolytic anemia and immune thrombocytopenia. In most cases, the underlying cause is unknown. We sought to identify genetic defects in pediatric ES (pES), based on a hypothesis of strong genetic determinism. In a national, prospective cohort of 203 patients with early-onset ES (median [range] age at last follow-up: 16.3 years ([1.2-41.0 years]) initiated in 2004, 80 nonselected consecutive individuals underwent genetic testing. The clinical data were analyzed as a function of the genetic findings. Fifty-two patients (65%) received a genetic diagnosis (the M+ group): 49 carried germline mutations and 3 carried somatic variants. Thirty-two (40%) had pathogenic mutations in 1 of 9 genes known to be involved in primary immunodeficiencies (TNFRSF6, CTLA4, STAT3, PIK3CD, CBL, ADAR1, LRBA, RAG1, and KRAS), whereas 20 patients (25%) carried probable pathogenic variants in 16 genes that had not previously been reported in the context of autoimmune disease. Lastly, no genetic abnormalities were found in the remaining 28 patients (35%, the M- group). The M+ group displayed more severe disease than the M- group, with a greater frequency of additional immunopathologic manifestations and a greater median number of lines of treatment. Six patients (all from the M+ group) died during the study. In conclusion, pES was potentially genetically determined in at least 65% of cases. Systematic, wide-ranging genetic screening should be offered in pES; the genetic findings have prognostic significance and may guide the choice of a targeted treatment.
small molecules
2026-09-30 | Case Report: Severe mixed autoimmune hemolytic anemia associated with acute cytomegalovirus infection in an immunocompetent adult.
Cytomegalovirus (CMV)-associated hemolytic anemia (HA) is rare in immunocompetent hosts and may present with heterogeneous serologic phenotypes, including direct antiglobulin test (DAT)-negative hemolysis, warm autoimmune hemolytic anemia (AIHA), cold antibody-mediated AIHA, and rarely mixed AIHA. Because mixed AIHA requires evidence of both warm autoantibodies and clinically significant cold autoantibody activity, this phenotype may be underrecognized without comprehensive immunohematologic testing. We report a case of CMV-associated HA that was diagnosed as mixed AIHA by comprehensive immunohematologic assessment and successfully managed with combination therapy. A 59-year-old immunocompetent man presented with a 7-day history of fever, sore throat, and fatigue. Initial evaluation revealed marked hepatocellular and cholestatic liver injury, positive CMV IgM with negative CMV IgG, and serum CMV DNA of 2.28 × 105 IU/mL. After exclusion of common viral and autoimmune causes, acute CMV hepatitis was clinically diagnosed. On hospital day 4, he developed dark brown urine, with hemoglobin falling to 40 g/L and laboratory evidence of acute hemolysis. Extended DAT revealed IgG, IgA, IgM, and C3d coating of erythrocytes, and cold agglutinin testing identified an IgM cold agglutinin with a titer of 1:128 and thermal amplitude extending to 37 °C, supporting severe CMV-associated mixed AIHA. After antiviral therapy, immunomodulatory and supportive treatment, hemolysis was controlled, and hemoglobin stabilized without further transfusion. CMV-associated HA may rarely present as severe mixed AIHA in immunocompetent adults. In severe or atypical cases, comprehensive immunohematologic evaluation beyond routine DAT, including extended DAT, cold agglutinin titration, and thermal amplitude testing, is essential for accurate subtyping. In severe cases, early integrated therapy targeting both CMV replication and immune-mediated hemolysis may be required.
2026-09-11 | DAT-negative autoimmune hemolytic anemia following acute hepatitis a in a pediatric patient with elevated IgA: a rare case report and literature review.
Acute hepatitis A (AHA) is typically self-limited, with complications occurring in only 0.1% of patients. Autoimmune hemolytic anemia (AIHA) following AHA is exceedingly rare; only four adult cases have been reported. We present the first documented pediatric case of DAT-negative AIHA following severe AHA. A 13-year-old Middle Eastern female presented with worsening jaundice, dark urine, and breathlessness 4 weeks after a confirmed AHA diagnosis. Laboratory evaluation revealed hemolysis: hemoglobin 8.1 g/dL, LDH 560 U/L, haptoglobin 0.14 g/L, reticulocyte count 7.28%, and indirect bilirubin 19.3 mg/dL. The direct antiglobulin test (DAT) was negative on three occasions. Extensive testing excluded Glucose-6-phosphate dehydrogenase deficiency, thalassemias, hereditary spherocytosis, malignancies, and other autoimmune diseases. Immunoglobulin studies showed elevated IgA (596.2 mg/dL) with normal IgG and IgM. Diagnosis of DAT-negative AIHA was established through the exclusion of hereditary causes and confirmed by a rapid response to prednisolone 1 mg/kg/day (hemoglobin rose from 8.1 to 10.4 g/dL within 1 week). This case highlights that 3-11% of AIHA cases are DAT-negative due to IgA or IgM antibodies or low-affinity IgG. DAT-negative AIHA should be suspected in unexplained post-viral hemolysis despite a negative DAT. Early empiric corticosteroids can be both diagnostic and therapeutic. Key clinical lessons: (1) DAT-negative AIHA accounts for 3-11% of cases and may be IgA-mediated; (2) Systematic exclusion of hereditary hemolytic anemias is essential in high-prevalence populations; (3) Rapid response to corticosteroids supports immune-mediated etiology and justifies continued treatment.
2026-08-24 | Bortezomib and autoimmune hemolytic anemia: a systematic review and meta-analysis
Conventional treatments for autoimmune hemolytic anemia (AIHA) are associated with drawbacks including high recurrence rates and limited therapeutic efficacy. As a proteasome inhibitor, bortezomib demonstrates potential value in relapsed/refractory AIHA, yet existing evidence mostly consists of small-sample case reports without quantitative integrated analyses. The results of this meta-analysis revealed that the pooled overall response rate (ORR) of bortezomib for AIHA was 81% (95%CI: 0.71–0.92), with extremely low inter-study heterogeneity (I²=0.0%, P=0.950). After excluding 2 conference abstracts, the pooled ORR of the remaining 4 full-text studies reached 82% (95%CI: 0.69–0.94), and leave-one-out sensitivity analysis identified no single study exerting a significant impact on the overall conclusions. Current evidence indicates that bortezomib can serve as a second-line salvage therapy for relapsed/refractory patients. However, the included studies were predominantly single-arm retrospective small-sample trials, lacking long-term safety data, failing to differentiate therapeutic effects between warm-type AIHA and cold agglutinin disease subgroups, and containing no controlled trials for direct comparisons with conventional regimens. In conclusion, bortezomib delivers stable efficacy and acceptable tolerability in relapsed/refractory AIHA. Large-sample, multicenter, prospective controlled studies are still required to clarify the optimal administration regimen, eligible patient populations and long-term safety profiles.
2026-08-10 | Autoimmune hemolytic anemia in the era of immunotherapy: from pathogenesis to therapeutic strategies
Abstract Autoimmune hemolytic anemia (AIHA) is a rare hematologic disorder characterized by the accelerated destruction of red blood cells mediated by autoantibodies and is classified into warm antibody type and cold antibody type. Corticosteroids remain the first-line treatment, whereas rituximab has replaced splenectomy as the standard second-line therapy. However, a considerable proportion of patients still experience relapse or refractory disease. In recent years, with an improved understanding of its pathogenesis, significant advances have been achieved in targeted therapies for AIHA, including complement inhibitors, spleen tyrosine kinase inhibitors, Bruton tyrosine kinase inhibitors, phosphoinositide 3-kinase delta inhibitors, other novel agents, and chimeric antigen receptor T-cell therapy. Future AIHA management will focus on individualized treatment guided by precise stratification, combination strategies, and biomarkers, ultimately achieving a transition from empirical immunosuppression to mechanism-targeted precision medicine.
2026-08-04 | Early-Onset Direct Antiglobulin Test-Negative Autoimmune Hemolytic Anemia Induced by Pembrolizumab in Perioperative Triple-Negative Breast Cancer: A Case Report.
Hematological immune-related adverse events associated with immune checkpoint inhibitors (ICIs) are rare, and autoimmune hemolytic anemia (AIHA) is particularly uncommon. A 71-year-old woman with stage IIA triple-negative breast cancer received perioperative pembrolizumab with carboplatin and paclitaxel. During the first treatment cycle, she developed acute severe anemia with laboratory findings consistent with hemolysis. Despite a negative direct antiglobulin test (DAT), major alternative causes of hemolysis were considered unlikely, leading to a clinical diagnosis of suspected ICI-associated AIHA. Oral prednisolone (1 mg/kg) promptly resolved hemolysis without recurrence. Pembrolizumab was discontinued; however, imaging demonstrated a clinical complete response, and subsequent surgery confirmed a pathological complete response (pCR). This case demonstrates that AIHA during ICI therapy may occur despite a negative DAT and underscores the importance of prompt recognition and corticosteroid therapy. Favorable oncologic outcomes, including pCR, may still be achieved despite early discontinuation of ICI therapy.
cell therapies
2026-09-11 | Therapeutic plasma exchange across multiple organ systems in an Egyptian tertiary center: A seven-year real-world cohort study.
Real-world evidence on therapeutic plasma exchange (TPE) from low- and middle-income countries remains limited. Egyptian data across multiple organ systems are scarce. This study aimed to evaluate the indications, safety, efficacy, and predictors of outcomes in patients undergoing TPE at a tertiary center in Egypt over 7 years. This retrospective cohort study included 221 consecutive patients who underwent TPE (2016-2022) at Zagazig University Hospitals, Egypt. Patients were stratified into renal, neurologic, hematologic, and metabolic groups. Primary outcomes were clinical response and all-cause mortality. Multivariate logistic regression, Cox proportional hazards models, and Kaplan-Meier survival analysis were performed. Among 221 patients (57.9% male; mean age 36.0 years), the most frequent indications were Guillain-Barré syndrome, thrombotic thrombocytopenic purpura, and myasthenia gravis crisis. ASFA category I indications constituted 77.8% of procedures, with response rates decreasing significantly across categories (p = 0.03). Overall response rate was 77.9% (complete remission in 93.0% of responders), with mortality 14.5%. Response rates exceeded 85% in autoimmune hemolytic anemia, hyperviscosity syndrome, and TTP. Neurologic indications achieved 81.6% response; renal indications showed lower response (73.2%) and highest mortality (21.3%). Adverse events occurred in 37.2% of patients, all mild-to-moderate with no session terminations. Independent mortality predictors included mechanical ventilation, creatinine >2.5 mg/dL, renal indication, hemoglobin <8 g/dL, while ASFA category I was protective (all aORs 2.67-5.22). In exploratory analyses, PLASMIC score ≥6 and time to TPE ≤ 2 days were associated with complete remission in TTP, while Hughes score ≥4 and time to TPE > 7 days were associated with poor functional outcome in GBS. These findings require external validation before clinical application. Diffuse alveolar hemorrhage (n = 9) demonstrated 100% mortality despite intervention, whereas SLE patients (n = 23) had 52.2% mortality, with 47.8% achieving complete remission or clinical improvement. A three-tier risk model stratified patients into high, intermediate, and low mortality risk groups. Independent predictors of clinical response included neurologic, hematologic, and metabolic indications compared to renal, ASFA category I, and ≥5 TPE sessions, while hemoglobin <8 g/dL and creatinine >2.5 mg/dL predicted poorer response. This single-center Egyptian TPE cohort demonstrates high efficacy and safety when aligned with ASFA guidelines. Neurologic and hematologic indications achieve optimal outcomes; renal indications and critical illness markers predict poorer prognosis. The PLASMIC score, treatment urgency in TTP and GBS, and the proposed three-tier model represent exploratory findings that, if prospectively validated, could become actionable prognostic tools. These findings suggest that evidence-based TPE expansion in resource-limited settings may be feasible, though multicenter validation is required.
2026-07-17 | Long-Term Survival, Illness Severity, and Time-to-Treatment Analysis in Dogs with Immune-Mediated Hemolytic Anemia Following Intravenous Allogeneic Mesenchymal Stem Cell Therapy: A Multicohort Follow-Up Study.
Steroid-refractory immune-mediated hemolytic anemia (IMHA) in dogs carries high early mortality, and the 15%-30% of cases that fail corticosteroid-based therapy represent a population with few effective options and a narrowing treatment window. In a prior retrospective study, intravenous allogeneic mesenchymal stem cell (MSC) therapy achieved a 76.7% hematological success rate in 43 dogs with steroid-refractory IMHA. The present multicohort follow-up study extends that work by characterizing illness severity, time-to-treatment, and long-term survival across 137 eligible patients from the same database. In Kaplan-Meier analysis of all 137 eligible patients, comprising both the nonsurvivor cohort (n = 57) and the lifespan registry (n = 80), median survival was 1,695 days (4.6 years) in the primary cohort and was not reached in the protocol-assessable cohort (n = 120). Estimated 1-year survival was 56.9% (95% CI: 48.2%-64.7%) and 65.0% (95% CI: 55.7%-72.8%), respectively, and the survival probability stabilized at approximately 52% through 8.1 years of follow-up. Among the 57 nonsurvivors, 51 had sufficient diagnostic data to calculate a Canine Hemolytic Anemia Objective Score (CHAOS) score; two-thirds (66.7%) met the high-risk threshold (CHAOS ≥ 3) at diagnosis. This exceeds the approximately 50% estimated from a published multicenter reference population, indicating that the Safari nonsurvivor cohort was enriched for severely ill dogs at presentation. Median post-treatment survival in nonsurvivors was 8 days (IQR: 3-38), and dogs receiving only one MSC dose had markedly shorter survival than those receiving two or more (median 4 vs. 19 days, P < 0.01), consistent with fulminant disease limiting completion of therapy rather than treatment failure. Diagnosis-to-treatment delay was shorter in survivors than in nonsurvivors (median 13 vs. 25 days), an exploratory finding warranting prospective evaluation. Taken together, these findings suggest that nonsurvival reflects the severity of the underlying disease and that dogs who respond to MSC therapy have potential for durable multiyear remission.
2026-07-06 | Immune cell-derived membrane nanovesicles: A promethean fire for autoimmune disease therapy through immune cell mimicry.
Autoimmune diseases (AIDs) constitute a heterogeneous group of disorders characterized by immune dysregulation, loss of self-tolerance, and chronic inflammation, which leads to tissue damage and organ dysfunction. Current therapies for AIDs are often limited by their lack of specificity, systemic side effects, and insufficient restoration of immune tolerance. Recent advances in nanotechnology and bioengineering have introduced immune and associated cell-derived membrane vesicles (IACMVs) as a promising therapeutic platform. Derived from macrophages, dendritic cells, neutrophils, platelets, or red blood cells, IACMVs inherit key surface proteins and receptors from their parent cells, conferring endogenous biocompatibility, inflammation-specific targeting, and intrinsic immunomodulatory capabilities. These vesicles can be engineered to carry therapeutic cargoes (e.g., peptide inhibitors, nucleic acids) or modified with surface ligands to enhance disease-site specificity, making them versatile tools for specific immunomodulation. This review provides a comprehensive overview of IACMVs, focusing on their preparation techniques, functional mechanisms, and therapeutic applications in prototypical AIDs such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), autoimmune hemolytic anemia (AIHA), type 1 diabetes (T1D), multiple sclerosis (MS), and autoimmune myocarditis (AM). We highlight translational challenges, including production scalability, membrane integrity, immunogenicity, and cargo-loading efficiency, that must be addressed to advance clinical translation. Finally, we discuss future directions for optimizing IACMVs as next-generation, safe, and targeted immunotherapeutic platforms for AIDs.
2026-06-03 | Stealth red blood cells with broad-spectrum antigenic shielding for transfusion therapy in antibody-mediated hemolytic anemia.
Red blood cell (RBC) transfusion is a cornerstone of life-sustaining therapy, yet it is profoundly challenged in autoimmune hemolytic anemia (AIHA). In this disorder, a diverse array of autoantibodies targets both the autologous and transfused RBCs, leading to their rapid clearance. This limitation is especially severe during hemolytic crises, rendering conventional transfusion ineffective and eliminating a critical therapeutic option. To overcome this, we developed a biocompatible strategy by utilizing a microbial transglutaminase that first anchors to the RBC membrane and then crosslinks a polysialic acid (PSA) network onto the cell surface. This created an immunologically inert shield that broadly masks surface antigens from pathogenic antibodies. Crucially, this "stealth" modification preserved the RBCs' native biological functions, including essential gas exchange, while conferring robust resistance to antibody-mediated hemolysis. In vitro, the engineered RBCs were protected from antibody binding and macrophage phagocytosis. This protection translated to a significantly prolonged circulation time in AIHA murine models and demonstrated excellent biocompatibility in an allogeneic transfusion setting. Our findings underscore the significant potential of this platform to enable effective, life-saving transfusion therapies for AIHA and other antibody-mediated disorders.
2026-05-02 | A case of autoimmune hemolytic anemia with acquired functional mutation of the TLR7.
This article presents a case of recurrent autoimmune hemolytic anemia in a child with a gain-of-function (GOF) mutation of the TLR7. This patient's condition contrasts with the six previously documented cases of GOF mutations in the TLR7, thereby expanding the phenotypic spectrum of such mutations and enhancing clinical comprehension of childhood systemic lupus erythematosus (cSLE). The article discusses the mechanisms by which TLR7 GOF mutations can result in autoimmune hemolytic anemia, explores the influence of cytomegalovirus (CMV) infection on the disease's development and progression, and emphasizes the therapeutic potential of hematopoietic stem cell transplantation for cases of TLR7 GOF mutations.
proteins
2026-05-18 | Case Report: Different faces of LRBA deficiency in five Moroccan families.
LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency belonging to the spectrum of common variable immunodeficiency disorders, frequently associated with immune dysregulation, autoimmunity, and lymphoproliferation. Its clinical presentation is highly heterogeneous, ranging from isolated autoimmune cytopenias to severe multisystem involvement. Here, we report five cases of LRBA deficiency from five Moroccan families, highlighting the broad clinical variability of this condition. The first patient presented with chronic immune thrombocytopenic purpura (ITP) as the initial and predominant manifestation, associated with hypogammaglobulinemia. The second patient developed ITP complicated by a hemorrhagic syndrome and significant lymphoproliferation, including splenomegaly and hepatomegaly. The third patient initially presented with autoimmune hemolytic anemia (AIHA), followed by splenomegaly. The fourth patient exhibited a complex clinical course, beginning with bicytopenia and progressing to enteropathy, arthritis, pneumopathy, and type 1 diabetes mellitus, associated with splenomegaly, hepatomegaly, and lymphadenopathy. Finally, the fifth patient initially presented with ITP and subsequently developed bilateral panuveitis, arthritis, and recurrent respiratory infections. Targeted next-generation sequencing identified homozygous pathogenic variants in the LRBA gene in all five patients, consistent with a loss-of-function mechanism. These included the nonsense variants c.3811C>T (p.Arg1271*) and c.5692G>T (p.Glu1898*), a large deletion encompassing exons 30 to 34, the frameshift variant c.5060_5067delACATACCA (p.Asn1687Serfs*21), and an extended deletion involving part of exon 4 (c.476_549 + 580del). All patients required immunosuppressive therapy and/or immunoglobulin replacement. LRBA deficiency should be considered in children presenting with autoimmune cytopenias, lymphoproliferation, and multisystem autoimmunity. The marked heterogeneity of clinical manifestations underscores the importance of early molecular diagnosis to guide therapeutic decision-making. In our experience, prompt recognition and the initiation of targeted therapies, such as abatacept or early hematopoietic stem cell transplantation, may improve patient outcomes.
2025-11-03 | Mixed autoimmune hemolytic anemia as a rare initial presentation of systemic lupus erythematosus
Abstract Introduction: Autoimmune hemolytic anemia (AIHA) is a rare disorder in which autoantibodies produced by the immune system attach to red blood cells, leading to their premature destruction. It is primarily divided into warm IgG antibodies (65% prevalence), cold C3 antibodies (15-20% prevalence), and mixed IgG and C3 antibodies (10% prevalence) based on antibody agglutination temperature. Mixed autoimmune hemolytic anemia (MAIHA) is an exceedingly rare disorder that usually presents as severe anemia with a median hemoglobin of 6. We report a rare case of a patient who presented with MAIHA as an initial presentation of SLE. Case Description:A 22-year-old Hispanic female, with no past medical history, presented to the emergency department with complaints of RUQ abdominal pain, fatigue, and dark discoloration of urine for 2 weeks. Initial labs showed a hemoglobin of 5.3 g/dL, an RBC count of 1.28 million/mcL, MCV of 126 fL, an elevated total bilirubin of 2.7 mg/dL (with an indirect bilirubin of 2.1 mg/dL), a high LDH of 278 U/L, and a significantly low haptoglobin of less than 30 mg/dL. The Direct Coombs Test (DAT) was positive with both polyspecific and C3 reagents, and the Antibody Screen was positive on both the Immediate Spin and Prewarm Indirect Coombs tests. Furthermore, a positive antibody screen was noted, and both warm and cold autoantibodies were identified. Iron studies, folate, and B-12 levels were within normal limits. The patient was started on immunosuppressive therapy for mixed autoimmune hemolytic anemia with prednisone 1 mg per kilogram divided into twice daily dosing and IVIG 1g/kg for two doses. She did not receive any blood transfusion because of no overt signs of bleeding and lack of availability of cross-matched blood. Her hemoglobin improved to 5.8 after the first dose of steroids and IVIG. On further testing, infectious workup was negative for influenza virus, RSV, SARS-CoV-2, HIV, hepatitis panel, EBV, and CMV. C4 levels were low at 9, and C3 levels were normal. Her ANA screen was positive, and the double-stranded DNA antibody level was 18 UL/ml. The patient met SLICC criteria for SLE, manifested with positive ANA by IFA 1:1280, positive dsDNA, low complement level, and hemolytic anemia. The patient continued to improve on prednisone. She was discharged on the eighth day of her hospitalization on oral prednisone at 45 mg twice daily. Her hemoglobin on the day of discharge was 7.6 g/dL, hematocrit 21.7%, and the RDW was 24.5% Discussion: MAIHA is associated with autoimmune diseases, lymphoproliferative disorders, and infections. SLE is the most common autoimmune disorder associated with mixed AIHA. Autoimmune hemolysis occurs in about 10% of patients with SLE; however, MAIHA is rarely the presenting feature. The primary treatment of MAIHA is corticosteroid therapy and avoiding exposure to cold. Our patient achieved remission with steroids and IVIG. We preferred IVIG as it is faster acting than rituximab and has fewer side effects. IVIG inhibits extravascular hemolysis by saturating the reticuloendothelial system. Most patients require more than one therapeutic intervention for AIHA.Conclusion: This case highlights that although rare, SLE can present with MAIHA. SLE should be considered as one of the causes of MAIHA, and clinicians should have a high clinical suspicion for it.
2025-06-12 | Evans Syndrome and COVID-19 Infection or Vaccination: A Systematic Review of Case Reports.
Evans syndrome (ES) is an autoimmune disorder of unknown etiology characterized by autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). In this systematic review, we analyzed the reported cases of ES secondary to coronavirus disease 2019 (COVID-19) infection or COVID-19 vaccination. We examined their clinical presentation, temporality between events, diagnostics tests, and treatment regimens. Our search in four databases from December 2019 to September 2023 yielded 16 case reports that met eligibility criteria for inclusion. COVID-19 and ES symptoms were defined to assess the timeline between infection/vaccination and ES onset. Finally, treatment efficacy was categorized as complete, partial, or no response based on standard hematological criteria. Eleven cases of ES were associated with COVID-19 infection, and five cases of ES were associated with COVID-19 vaccination. All 16 cases presented with anemia, thrombocytopenia, and a positive Coombs test. Four of the five patients from the vaccination subset were found to have an additional autoimmune disease as a comorbidity on presentation. For cases of ES secondary to COVID-19 infection, six patients had concomitant symptoms of COVID-19 and ES on presentation, and four patients had ES symptoms occurring from 5 days to 3 weeks following COVID-19 infection. The remaining case presented a patient with a 3-week history of ES symptoms before a positive COVID-19 test and further ES workup on admission. For the five cases of ES post-COVID-19 vaccination, all five patients presented with ES with a mean presentation time of 9 days following vaccination. Regarding treatment, intravenous immunoglobulin (IVIG) emerged as the primary regimen, administered in 13 out of the 16 cases. Among the infection-related cases, the most frequent treatment outcome was a partial response in both AIHA and ITP, observed in five of the 11 patients. In the vaccination-related cases, a partial response for AIHA and a complete response for ITP were noted in three of the five patients. Overall, while the evidence points to a temporal association especially between COVID-19 vaccination and the onset of ES, larger studies are necessary to strengthen these findings. In terms of management, early initiation of corticosteroids and IVIG appears effective as first-line therapies; however, standardized treatment protocols are needed to help reduce complications associated with COVID-19-related ES.
2025-04-18 | Epstein-Barr virus-associated autoimmune hemolytic anemia: a clinical report and review of literature.
Epstein-Barr virus (EBV) infection is a common disease both in children and adults, but can lead to several complications; involvement of the blood system is often described, particularly neutropenia and thrombocytopenia, but autoimmune hemolytic anemia is rarely seen. A 12-year-old female was admitted to the "G. Di Cristina" Children's Hospital of Palermo for jaundice and dark urine. Laboratory investigations revealed anemia, increased levels of total and undirect bilirubin, and elevated transaminases, serum lactate dehydrogenase, and reticulocyte count; a peripheral blood smear showed anisocytosis, and the direct antiglobulin test (DAT) for cold agglutinins was positive. The laboratory evaluation of infectious disease showed the presence of EBV VCA IgM and IgG. A diagnosis of acute autoimmune hemolytic anemia EBV related was made: the patient was initially treated with intravenous methylprednisolone and then with intravenous immunoglobulin, which led to a progressive clinical improvement until complete remission. Autoimmune hemolytic anemia is rarely associated with EBV infection; a review of the English literature revealed only 16 cases. Patients with autoimmune hemolytic anemia should always be evaluated for EBV serology, even in the absence of the typical clinical and hematological features of infectious mononucleosis. For these patients, good prognosis is generally expected.
2024-10-23 | Potent efficacy of an IgG-specific endoglycosidase against IgG-mediated pathologies.
Endo-β-N-acetylglucosaminidases (ENGases) that specifically hydrolyze the Asn297-linked glycan on immunoglobulin G (IgG) antibodies, the major molecular determinant of fragment crystallizable (Fc) γ receptor (FcγR) binding, are exceedingly rare. All previously characterized IgG-specific ENGases are multi-domain proteins secreted as an immune evasion strategy by Streptococcus pyogenes strains. Here, using in silico analysis and mass spectrometry techniques, we identified a family of single-domain ENGases secreted by pathogenic corynebacterial species that exhibit strict specificity for IgG antibodies. By X-ray crystallographic and surface plasmon resonance analyses, we found that the most catalytically efficient IgG-specific ENGase family member recognizes both protein and glycan components of IgG. Employing in vivo models, we demonstrated the remarkable efficacy of this IgG-specific ENGase in mitigating numerous pathologies that rely on FcγR-mediated effector functions, including T and B lymphocyte depletion, autoimmune hemolytic anemia, and antibody-dependent enhancement of dengue disease, revealing its potential for treating and/or preventing a wide range of IgG-mediated diseases in humans.
antibodies
2026-09-27 | Autoimmune Hemolytic Anemia Complicated by Portal Vein Thrombosis in a Pediatric Liver Transplant Recipient: A Case Report.
Post-transplant autoimmune hemolytic anemia (AIHA) occurs in approximately 1% to 3% of pediatric liver transplant recipients. Its co-occurrence with portal vein thrombosis (PVT) is exceedingly rare and potentially life-threatening. We report a 10-month-old female who underwent living-donor liver transplantation for biliary atresia and presented with AIHA 5 months later. Laboratory evaluation revealed severe hemolytic anemia (hemoglobin 7.5 g/dL), markedly elevated lactate dehydrogenase (1751 IU/L), hyperbilirubinemia (total bilirubin 4.92 mg/dL), thrombocytopenia (75 × 103/μL), prolonged PT/INR, critically reduced Protein S activity (48.1%), and elevated D-dimer (3.78 mg/L; 7.6 × upper normal). A strongly positive Direct Antiglobulin Test confirmed AIHA. Abdominal computed tomography demonstrated hepatomegaly with portal vein thrombosis, confirmed by color-flow Doppler ultrasonography with turbulent, reduced flow. Tacrolimus dose was reduced and simultaneous high-dose methylprednisolone (4 mg/kg/d intravenously), rituximab, and therapeutic heparin were initiated. Complete portal vein recanalization was confirmed by Doppler on Day 5, with full immunologic remission (Direct Antiglobulin Test-negative) thereafter. This case demonstrates that post-transplant AIHA can precipitate PVT through a hemolysis-driven hypercoagulable cascade involving Protein S consumption, thrombocytopenia, and pro-coagulant erythrocyte microparticle release. Systematic coagulation profiling and Doppler ultrasonography at AIHA onset are mandatory in pediatric liver transplant recipients to prevent potentially fatal vascular complications.
2026-09-26 | Pediatric DOCK8 Deficiency Beyond Infections and Atopy: An Immunoactinopathy with Immune Dysregulation and Multisystem Involvement.
Background/Objectives: Dedicator of cytokinesis 8 (DOCK8) deficiency is an autosomal recessive combined immunodeficiency and an actin cytoskeleton-related inborn error of immunity characterized by severe atopy, recurrent infections, and broad immune dysregulation. We aimed to describe the clinical, immunological, genetic, treatment-related, and outcome features of children with genetically confirmed DOCK8 deficiency, emphasizing immune dysregulation and systemic involvement. Methods: We retrospectively reviewed 17 pediatric patients from 14 unrelated kindreds with genetically confirmed DOCK8 deficiency followed at a tertiary pediatric immunology center between 2005 and 2026. Demographic data, infectious and allergic manifestations, autoimmune and hematological findings, organ involvement, malignancy, laboratory parameters, genetic findings, hematopoietic stem cell transplantation (HSCT) status, and survival outcomes were analyzed descriptively. Results: Twelve patients were male (70.6%), and parental consanguinity was present in 13 patients (76.5%). The median age at symptom onset was 5 months (IQR, 3-10), whereas the median age at diagnosis was 44 months (IQR, 23-56). A history of eczema was documented in all patients. Recurrent skin infections occurred in 16 patients (94.1%), recurrent pneumonia in 13 (76.5%), mucocutaneous candidiasis in 10 (58.8%), and cytomegalovirus infection in four (23.5%). Confirmed autoimmune manifestations were documented in two patients, including autoimmune hepatitis and autoimmune hemolytic anemia. Malignancy occurred in two patients: gastrointestinal stromal tumor and cutaneous squamous cell carcinoma. Additional uncommon systemic manifestations included sclerosing cholangitis, giant aortic aneurysm, and chronic pancreatitis. HSCT was performed in 12 patients (70.6%); complete clinical recovery was achieved in 11, whereas one patient died after transplantation. Four of five non-transplanted patients died during follow-up. Conclusions: Pediatric DOCK8 deficiency showed an early-onset, severe, multisystem phenotype. Beyond infections and atopy, immune dysregulation-related and systemic manifestations were clinically important. Favorable HSCT outcomes were consistent with previous evidence supporting early molecular diagnosis and timely transplant evaluation.
2026-09-25 | Mixed Autoimmune Hemolytic Anemia as the Initial Manifestation of Systemic Lupus Erythematosus: A Case Report
Mixed autoimmune hemolytic anemia (mAIHA) is a rare subtype of autoimmune hemolytic anemia (AIHA) characterized by the coexistence of warm (immunoglobulin G (IgG)) and cold (immunoglobulin M (IgM)) autoantibodies.It may occur as a primary disorder or secondary to underlying conditions, including systemic lupus erythematosus (SLE).We report the case of a 16-year-old female who presented with severe hemolytic anemia as the initial manifestation of SLE.On admission, her hemoglobin was 34 g/L with marked reticulocytosis and a positive direct antiglobulin test (DAT) demonstrating both IgG and IgM antibodies, confirming mAIHA.Immunological investigations revealed positive antinuclear antibody (ANA), antidouble-stranded DNA (anti-dsDNA) antibody, and anti-Smith antibody, supporting a diagnosis of SLE.At the time of the first presentation, she had no other clinical features suggestive of SLE.She was treated with blood transfusions and corticosteroids, resulting in significant improvement, and was discharged on a tapering prednisolone regimen.Shortly after, she was readmitted with a malar rash, arthralgia, joint swelling, nephrotic-range proteinuria, and worsening renal function.She was subsequently diagnosed with SLE complicated by lupus nephritis and recurrent AIHA.Following the rheumatology and nephrology review, she received intravenous methylprednisolone and was transferred to a tertiary care center for renal biopsy and further management.Renal biopsy demonstrated focal segmental glomerulosclerosis (FSGS).Further treatment with prednisolone, mycophenolate mofetil, intravenous belimumab, and hydroxychloroquine resulted in an excellent clinical response, with follow-up confirming remission.This case highlights mAIHA as a rare initial presentation of SLE and underscores the importance of early recognition, close monitoring, and multidisciplinary management, as patients presenting with AIHA may be at increased risk of developing lupus nephritis and other severe SLE-related complications.
2026-09-24 | Sustained clinical stability with telitacicept-containing maintenance therapy following glucocorticoid and IVIG induction for lupus enteritis with autoimmune hemolytic anemia: a case report.
Lupus mesenteric vasculitis (LMV) is a rare but potentially life-threatening complication of systemic lupus erythematosus, with reported mortality rates of up to 13.4% despite aggressive immunosuppression. Standard management relies on high-dose glucocorticoids (GCs) combined with cyclophosphamide (CYC) or mycophenolate mofetil (MMF); however, prolonged glucocorticoid dependence and disease recurrence remain significant clinical challenges. Telitacicept, a recombinant transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI)-Fc fusion protein that simultaneously neutralizes B-lymphocyte stimulator and a proliferation-inducing ligand, has demonstrated efficacy in active SLE, yet evidence for its use in LMV is limited to a single case report. We describe a 27-year-old female with severe, glucocorticoid-dependent LMV complicated by autoimmune hemolytic anemia (AIHA), who received pulse methylprednisolone (MP) and intravenous immunoglobulin (IVIG) for acute induction, followed by telitacicept 160 mg weekly as part of a combination maintenance regimen. After conventional induction, telitacicept was associated with successful prednisone tapering from 60 mg/day to 10 mg/day over approximately 6 months without disease flare, accompanied by sustained normalization of hemoglobin and complement levels, and radiological improvement. This case represents the second report of telitacicept for LMV and the first to document sustained resolution of AIHA maintained during telitacicept-containing therapy. The induction with pulse MP followed by telitacicept maintenance and accelerated steroid taper" strategy may offer a promising therapeutic option for refractory LMV warranting further prospective investigation.
2026-09-14 | IgA driven autoimmune hemolytic anemia: a monocentric Italian report and literature review.
Atypical autoimmune hemolytic anemias (AIHA) include DAT-negative forms and those driven by IgA autoantibodies. IgA-mediated AIHA is rare, with limited evidence on clinical severity and management beyond first-line steroids. We revised our series of IgA-mediated AIHA and reviewed the literature. We retrospectively evaluated patients with IgA-positive AIHA followed at a tertiary hematologic center in Milan since May 1978. Published reports from 2010 to January 28, 2025 were also reviewed. Thirteen patients with IgA-mediated AIHA were identified among 409 AIHA cases. Median age was 60 years, and 69.2% were female. Fatigue was the most common symptom; mean hemoglobin was 7.9 g/dL. Dual IgA/IgG positivity occurred in 69.2%, while triple IgA/IgG/IgM positivity occurred in 7.7%. All but one patient received corticosteroids, 33% rituximab, 16.6% IVIg, and 23.1% transfusions. One patient received bortezomib followed by mycophenolate mofetil and plasma exchange. During a median follow-up of 36 months, 63.6% relapsed. Infections and thrombotic events occurred in 16.7% each, with no deaths. The literature review included 35 patients from 19 studies. Most were female (62%), aged 3 months to 77 years. Tachycardia and dyspnea were the most common symptoms; mean hemoglobin was 5.6 g/dL. DAT showed dual IgA/IgG or IgA/IgM positivity in 54.3%. Corticosteroids were administered to all reported patients, IVIg and rituximab to 14% and 23%, respectively. Splenectomy was performed in 6%, and 93% received transfusions. Infections occurred in 14%, thrombotic events in 7.1%, and one patient was refractory and died. IgA-mediated AIHA is a rare, heterogeneous subtype characterized by frequent dual antibody positivity, suboptimal corticosteroid response, and substantial risks of relapse and complications, requiring careful monitoring and individualized management. These findings highlight the need for improved recognition of IgA-mediated disease and prospective studies to define optimal second-line therapies and outcomes in affected patients.
other
2025-08-22 | From Yellow Cumulus to Pregnancy in Autoimmune Hemolytic Anemia Following Bilirubin Reduction: A Case Report.
Autoimmune hemolytic anemia (AIHA) is a systemic condition associated with inflammation and oxidative stress, both of which can negatively affect reproductive outcomes. Bilirubin, a byproduct of hemolysis, has been implicated in oocyte maturation and embryogenesis. We present the case of a 31-year-old patient with primary infertility who was known with AIHA. She had a total bilirubin level of 60 µmol/L prior to the first stimulation cycle, which was associated with yellowish pigmentation of the cumulus cells, poor oocyte quality, and no blastocyst formation. The decline in the total bilirubin level to 48 µmol/L after prednisone therapy of 60 mg daily for three months led to improved cumulus cell appearance and enhanced oocyte and embryo quality in the second stimulation cycle. A successful pregnancy was achieved following frozen blastocyst transfer in a natural cycle. This case underscores the importance of individualized assessment and the careful interpretation of elevated bilirubin levels in the context of assisted reproductive technology, as systemic conditions may potentially impact reproductive success.
2025-05-20 | Mixed Autoimmune Hemolytic Anemia: A Systematic Review of Epidemiology, Clinical Characteristics, Therapies, and Outcomes.
Mixed autoimmune hemolytic anemia (AIHA) is a rare and clinically complex hematologic disorder defined by the simultaneous presence of both warm and cold autoantibodies, resulting in severe and often treatment-resistant hemolysis. Due to variability in diagnostic criteria and limited data, a comprehensive understanding of its epidemiology, clinical characteristics, and management remains incomplete. To address these gaps, we performed a systematic literature review employing stringent diagnostic criteria to evaluate epidemiologic patterns, clinical features, and therapeutic outcomes. Our analysis included 81 patients identified across 35 studies, revealing a median age of 45 years and a notable female predominance (2.25:1). Autoimmune diseases constituted the most frequent underlying etiology, followed by hematologic malignancies and infections. Patients exhibited significant anemia, with median nadir hemoglobin levels reaching 5.6 g/dL. Corticosteroids represented the most common therapeutic intervention; however, only 43% of patients achieved remission, while 37% experienced chronic hemolysis, and mortality reached 11%. Many patients required multiple lines of therapy, including rituximab and cytotoxic agents, highlighting the disease's refractory nature and management complexity. The substantial variability in diagnostic and therapeutic approaches emphasizes an urgent need for standardized diagnostic criteria, earlier integration of combination therapies, and exploration of innovative treatment modalities. Future prospective, multicenter studies are essential to refine disease recognition, optimize therapeutic strategies, and ultimately improve patient outcomes in mixed AIHA.
2024-08-19 | Association of paediatric autoimmune cytopenia and inflammatory bowel disease suggests a common genetic origin.
The association of autoimmune cytopenia (AIC) and inflammatory bowel disease (IBD) has been reported in small series, but the incidence of and risk factors for IBD in children with AIC are not known. One thousand six hundred nine children with chronic immune thrombocytopenic purpura, autoimmune haemolytic anaemia or Evans syndrome from the prospective OBS'CEREVANCE cohort are included in this study. Overall, 15 children were diagnosed with IBD, including 14 who developed IBD after AIC diagnosis (median delay: 21 months). The only risk factor for IBD development is age at AIC over 10 years. Out of 10 children genetically tested, germline variants associated with autoimmune disorders were identified in three (CTLA4: two, DOCK11: one). In children and adolescents monitored for AIC or past history of AIC, especially children over 10 years, gastro-intestinal (GI) symptoms (recurrent abdominal pains, GI bleeding, chronic diarrhoea, weight loss) should suggest IBD and deserve specific work-up and genetic studies. Identification of a causal germline variant will allow targeted therapy.
2022-04-26 | Pathogenesis of Autoimmune Cytopenias in Inborn Errors of Immunity Revealing Novel Therapeutic Targets.
Autoimmune diseases are usually associated with environmental triggers and genetic predisposition. However, a few number of autoimmune diseases has a monogenic cause, mostly in children. These diseases may be the expression, isolated or associated with other symptoms, of an underlying inborn error of immunity (IEI). Autoimmune cytopenias (AICs), including immune thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA), autoimmune neutropenia (AN), and Evans' syndrome (ES) are common presentations of immunological diseases in the pediatric age, with at least 65% of cases of ES genetically determined. Autoimmune cytopenias in IEI have often a more severe, chronic, and relapsing course. Treatment refractoriness also characterizes autoimmune cytopenia with a monogenic cause, such as IEI. The mechanisms underlying autoimmune cytopenias in IEI include cellular or humoral autoimmunity, immune dysregulation in cases of hemophagocytosis or lymphoproliferation with or without splenic sequestration, bone marrow failure, myelodysplasia, or secondary myelosuppression. Genetic characterization of autoimmune cytopenias is of fundamental importance as an early diagnosis improves the outcome and allows the setting up of a targeted therapy, such as CTLA-4 IgG fusion protein (Abatacept), small molecule inhibitors (JAK-inhibitors), or gene therapy. Currently, gene therapy represents one of the most attractive targeted therapeutic approaches to treat selected inborn errors of immunity. Even in the absence of specific targeted therapies, however, whole exome genetic testing (WES) for children with chronic multilineage cytopenias should be considered as an early diagnostic tool for disease diagnosis and genetic counseling.
2020-01-09 | Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes.
Evans syndrome (ES) is a rare severe autoimmune disorder characterized by the combination of autoimmune hemolytic anemia and immune thrombocytopenia. In most cases, the underlying cause is unknown. We sought to identify genetic defects in pediatric ES (pES), based on a hypothesis of strong genetic determinism. In a national, prospective cohort of 203 patients with early-onset ES (median [range] age at last follow-up: 16.3 years ([1.2-41.0 years]) initiated in 2004, 80 nonselected consecutive individuals underwent genetic testing. The clinical data were analyzed as a function of the genetic findings. Fifty-two patients (65%) received a genetic diagnosis (the M+ group): 49 carried germline mutations and 3 carried somatic variants. Thirty-two (40%) had pathogenic mutations in 1 of 9 genes known to be involved in primary immunodeficiencies (TNFRSF6, CTLA4, STAT3, PIK3CD, CBL, ADAR1, LRBA, RAG1, and KRAS), whereas 20 patients (25%) carried probable pathogenic variants in 16 genes that had not previously been reported in the context of autoimmune disease. Lastly, no genetic abnormalities were found in the remaining 28 patients (35%, the M- group). The M+ group displayed more severe disease than the M- group, with a greater frequency of additional immunopathologic manifestations and a greater median number of lines of treatment. Six patients (all from the M+ group) died during the study. In conclusion, pES was potentially genetically determined in at least 65% of cases. Systematic, wide-ranging genetic screening should be offered in pES; the genetic findings have prognostic significance and may guide the choice of a targeted treatment.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
18 orphan drug designations for Autoimmune hemolytic anemia, including 3 approved therapies.
18 orphan drug designations for Autoimmune hemolytic anemia, including 3 approved therapies.
Drug | Therapy type | Orphan designation | Clinical trial status | Sponsor |
|---|---|---|---|---|
rituximab | antibodies | FDA | ODDIFACT SAS | |
Bispecific humanized IgG4 BCMA-directed CD3 T cell engager antibody | antibodies | FDA | Lakefront Biotherapeutics West LLC | |
rilzabrutinib | small molecules | FDA | Sanofi US Services Inc. | |
Rilzabrutinib | small molecules | EMA | Sanofi B.V. | |
rituximab | antibodies | FDA | Mabion S.A. | |
a humanized IgG4 monoclonal antibody, produced in CHO cells, that binds to and inhibits the activated form of the classical complement pathway (CP) specific serine protease, C1s | antibodies | FDA | Bioverativ USA Inc | |
Humanised IgG4 monoclonal antibody against active complement component 1, subcomponent s | antibodies | EMA | Sanofi B.V. | |
Parsaclisib | small molecules | EMA | Incyte Biosciences Distribution B.V. | |
rituximab | antibodies | FDA | Taxon Therapeutics Ltd. | |
parsaclisib | small molecules | FDA | Incyte Corporation | |
nipocalimab-aahu [Imaavy] | antibodies | FDA | Approved | Janssen Research & Development, LLC |
Recombinant complement-specific multimerized human IgG1 Fc | proteins | FDA | — | Gliknik, Inc. |
pegcetacoplan | peptides | FDA | Apellis Pharmaceuticals, Inc. | |
fostamatinib disodium | small molecules | FDA | Rigel Pharmaceuticals, INc. | |
sutimlimab-jome [Enjaymo] | antibodies | FDA | Approved | Recordati Rare Diseases Inc. |
Humanised IgG4 monoclonal antibody against total complement component 1, subcomponent s [Enjaymo] | antibodies | EMA | Approved | Recordati Rare Diseases |
Revimmune | antibodies | FDA | Accentia Biopharmaceuticals | |
Epoetin alpha | — | FDA | R. W. Johnson Pharmaceutical Research Institute |
“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.